QuidelOrtho CLO granted RSUs and stock options

QuidelOrtho Corporation’s Chief Legal Officer, Michelle A. Hodges, reported multiple equity transactions.

Accepted by SEC EDGAR 02/03/2026 - 07:49 PM EST

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

QuidelOrtho Corporation’s Chief Legal Officer, Michelle A. Hodges, reported multiple equity transactions. On January 30, 2026, she received 38,562 restricted stock units (RSUs) and 38,561 non-qualified stock options with an exercise price of $27.17, with vesting scheduled between 2027 and 2029 and the options expiring in 2036.

On January 31, 2026, previously granted RSUs for 1,610 and 1,814 shares converted into the same number of common shares at no cost. The company withheld 578 and 651 shares at $27.17 per share to cover tax obligations. After these transactions, she directly held 39,555 shares of common stock.

Insider Trade Summary

3,424 shares exercised/converted

Exercise 8 txns

Insider Hodges Michelle A

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,610	$0.00	$0.00
Exercise	Restricted Stock Units	1,814	$0.00	$0.00
Grant/Award	Common Stock	1,610	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	578	$27.17	$16K
Grant/Award	Common Stock	1,814	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	651	$27.17	$18K
Grant/Award	Restricted Stock Units	38,562	$0.00	$0.00
Grant/Award	Non-Qualified Stock Options	38,561	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 38,562 contracts (Direct); Non-Qualified Stock Options — 38,561 contracts (Direct); Common Stock — 39,555 shares (Direct)

Holdings Before and After: Restricted Stock Units, 3,424 to 38,562 contracts (Direct); Non-Qualified Stock Options, 0 to 38,561 contracts (Direct); Common Stock, 37,360 to 39,555 shares (Direct)

Footnotes (7)

F1. Reflects release of restricted stock units that were previously reported on a Form 4.
F2. Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units.
F3. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
F4. 38,562 shares will vest in equal installments on January 30, 2027, January 30, 2028 and January 30, 2029.
F5. 12,853 shares will vest on January 30, 2027; the remaining 25,708 shares will vest in equal installments on January 30, 2028 and January 30, 2029.
F6. 1,610 shares vested on each of January 31, 2024, January 31, 2025 and January 31, 2026.
F7. 3,628 shares vested on January 31, 2024; and 1,814 shares vested on each of January 31, 2025 and January 31, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did QuidelOrtho (QDEL) report for Michelle Hodges?

QuidelOrtho’s Chief Legal Officer, Michelle A. Hodges, reported new grants of restricted stock units and stock options plus RSU vesting into common shares. Some of the resulting shares were withheld to satisfy tax obligations, with updated direct common stock holdings reported afterward.

How many restricted stock units did QDEL grant to Michelle Hodges in January 2026?

On January 30, 2026, Michelle Hodges received a grant of 38,562 restricted stock units. Each unit represents one share of QuidelOrtho common stock, with the award scheduled to vest in equal installments across three future vesting dates through early 2029.

What stock options were awarded to QuidelOrtho (QDEL) Chief Legal Officer Michelle Hodges?

Michelle Hodges received 38,561 non-qualified stock options on January 30, 2026, with an exercise price of $27.17 per share. These options are scheduled to vest over several years and will expire on January 30, 2036, if not earlier exercised or forfeited.

How many QuidelOrtho (QDEL) RSUs vested and converted to common stock in January 2026?

On January 31, 2026, two sets of previously granted restricted stock units vested, converting 1,610 and 1,814 units into the same number of QuidelOrtho common shares. These vestings reflect multi-year RSU schedules described in the accompanying footnotes.

Why were some QuidelOrtho (QDEL) shares disposed of in Michelle Hodges’ Form 4?

Shares reported as disposed were withheld by QuidelOrtho to cover tax withholding obligations related to RSU vesting. Specifically, 578 and 651 common shares were withheld at $27.17 per share when RSUs converted into common stock upon their scheduled vesting.

How many QuidelOrtho (QDEL) shares does Michelle Hodges hold after these transactions?

After the January 31, 2026 transactions, Michelle Hodges directly held 39,555 shares of QuidelOrtho common stock. This figure reflects RSU conversions into common shares and the related share withholdings used to satisfy tax obligations at vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hodges Michelle A

(Last)

(First)

(Middle)

9975 SUMMERS RIDGE ROAD

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
QuidelOrtho Corp [ QDEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/31/2026		A		1,610⁽¹⁾	A	$0	38,970	D
Common Stock	01/31/2026		F		578⁽²⁾	D	$27.17	38,392	D
Common Stock	01/31/2026		A		1,814⁽¹⁾	A	$0	40,206	D
Common Stock	01/31/2026		F		651⁽²⁾	D	$27.17	39,555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽³⁾	01/30/2026		A		38,562		⁽⁴⁾	⁽⁴⁾	Common Stock	38,562	$0	38,562	D
Non-Qualified Stock Options	$27.17	01/30/2026		A		38,561		⁽⁵⁾	01/30/2036	Common Stock	38,561	$0	38,561	D
Restricted Stock Units	⁽³⁾	01/31/2026		M			1,610	⁽⁶⁾	⁽⁶⁾	Common Stock	1,610	$0	0	D
Restricted Stock Units	⁽³⁾	01/31/2026		M			1,814	⁽⁷⁾	⁽⁷⁾	Common Stock	1,814	$0	0	D

Explanation of Responses:

1. Reflects release of restricted stock units that were previously reported on a Form 4.

2. Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units.

3. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.

4. 38,562 shares will vest in equal installments on January 30, 2027, January 30, 2028 and January 30, 2029.

5. 12,853 shares will vest on January 30, 2027; the remaining 25,708 shares will vest in equal installments on January 30, 2028 and January 30, 2029.

6. 1,610 shares vested on each of January 31, 2024, January 31, 2025 and January 31, 2026.

7. 3,628 shares vested on January 31, 2024; and 1,814 shares vested on each of January 31, 2025 and January 31, 2026.

Remarks:

	/s/ Phillip S. Askim, attorney-in-fact for Michelle A. Hodges	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR